The Patent Finder

Proscan RX Pharma Inc.

Also on record
Records under this name other than patents Proscan RX Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 5 of 5 · Back to Proscan RX Pharma Inc.

PatentTitleStatus Expires Confidence
US 7,910,693Prostate cancer diagnosis and treatment
Lapsed on the fee record
Ended Mar 22, 2023 · From the USPTO record
Lapsed on the fee recordEnded Mar 22, 2023From the USPTO record
US 7,811,564Prostate cancer diagnosis and treatment
Lapsed on the fee record
Ended Oct 12, 2022 · From the USPTO record
Lapsed on the fee recordEnded Oct 12, 2022From the USPTO record
US 8,629,247Antibodies against prostate specific membrane antigen
Lapsed on the fee record
Ended Jan 14, 2022 · From the USPTO record
Lapsed on the fee recordEnded Jan 14, 2022From the USPTO record
US 8,512,702Prostate cancer diagnosis and treatment
Lapsed on the fee record
Ended Aug 20, 2021 · From the USPTO record
Lapsed on the fee recordEnded Aug 20, 2021From the USPTO record
US 8,101,713Prostate cancer diagnosis and treatment
Lapsed on the fee record
Ended Jan 24, 2020 · From the USPTO record
Lapsed on the fee recordEnded Jan 24, 2020From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited